

Mackenzie US Mid Cap Opportunities Fund


Fund snapshot

| | |
|------------------------|-------------------------|
| Inception date | 05/27/2020 |
| AUM (millions in CAD) | 1825.6 |
| Management Fee | 0.80% |
| MER | 1.05% |
| Benchmark | Russell Mid Cap |
| CIFSC Category | US Small/Mid Cap Equity |
| Risk Rating | Medium |
| Lead portfolio manager | Phil Taller |
| Investment exp. Since | 1991 |
| Target # of holdings | 25-50 |

Strategy Overview


- The Fund seeks to provide long-term capital growth and a reasonable rate of return by investing primarily in equity securities of mid-capitalization companies in the United States.
- The Fund seeks companies with strong management, good growth prospects and attractive financial metrics.
- Emphasis is also placed on paying reasonable prices for the growth that companies in the portfolio are expected to achieve.

Trailing returns %



| | 3 Mth | 1 Yr | 3 Yr | SI |
|-------------------|-------|-------|------|------|
| Excess return | -2.0 | -10.4 | -6.3 | -4.5 |
| % of peers beaten | 55 | 48 | 40 | NA |

Calendar returns %



| | 2024 | 2023 | 2022 | 2021 |
|-------------------|-------|------|------|------|
| Excess return | -10.4 | -2.0 | -6.5 | 5.1 |
| % of peers beaten | 48 | 47 | 31 | 75 |

Portfolio characteristics

| | Portfolio | Benchmark |
|-----------------------------|-----------|-----------|
| # of holdings | 33 | 810 |
| % top 10 holdings | 49.0 | 6.1 |
| Weighted average market cap | 28,224.6 | 41,179.1 |
| EPS growth (FY E) | 11.5 | 14.3 |
| Dividend yield | 0.3 | 1.6 |
| FCF margin | 16.8 | 14.5 |
| P/E Trailing 12M | 28.8 | 21.7 |
| P/E (forecast) | 22.4 | 19.3 |
| Net debt/EBITDA | -0.9 | 1.4 |
| ROE (latest FY) | 14.6 | 15.3 |

Performance metrics (3 year trailing)

| Metrics | Portfolio | Benchmark |
|----------------------|-----------|-----------|
| Standard Dev. | 15.2 | 16.3 |
| Sharpe Ratio | -0.1 | 0.3 |
| Tracking Error | 5.7 | - |
| Information Ratio | -1.1 | - |
| Alpha | -5.7 | - |
| Beta | 0.9 | - |
| Upside Capture (%) | 81.9 | - |
| Downside Capture (%) | 106.3 | - |

Regional breakdown

| Region | Portfolio | Benchmark | Relative Weight |
|------------------|-----------|-----------|-----------------|
| United States | 97.2 | 99.5 | -2.3 |
| Canada | - | 0.1 | -0.1 |
| Emerging Markets | - | 0.3 | -0.3 |
| Other | 2.8 | 0.1 | 2.7 |

Sector allocation

| Sector | Portfolio | Benchmark | Relative Weight |
|------------------------|-----------|-----------|-----------------|
| Financials | 8.8 | 16.7 | -7.9 |
| Energy | - | 5.3 | -5.3 |
| Materials | - | 5.3 | -5.3 |
| Industrials | 22.1 | 16.8 | 5.3 |
| Information Technology | 25.8 | 14.2 | 11.6 |
| Communication Services | - | 3.8 | -3.8 |
| Utilities | - | 5.7 | -5.7 |
| Consumer Staples | 3.7 | 4.8 | -1.1 |
| Consumer Discretionary | 0.8 | 10.7 | -9.9 |
| Real Estate | 4.8 | 7.5 | -2.7 |
| Health Care | 31.3 | 9.3 | 22.0 |
| Other | 2.7 | -0.1 | 2.8 |

Country allocation

| Country | Portfolio | Benchmark | RelativeWeight |
|---------------|-----------|-----------|----------------|
| United States | 97.2 | 99.5 | -2.2 |
| Argentina | - | 0.1 | -0.1 |
| Brazil | - | 0.3 | -0.3 |
| Canada | - | 0.1 | -0.1 |
| Other | 2.8 | - | 2.8 |

Currency exposure

| Region | Gross | Benchmark |
|--------|-------|-----------|
| CAD | 9.3 | - |
| USD | 90.7 | 100.0 |

Top 10 holdings

| Security name | Country | Sector | Weight |
|------------------------------------------------|---------------|------------------------|--------|
| DexCom, Inc. | United States | Health Care | 5.6 |
| Akamai Technologies, Inc. | United States | Information Technology | 5.1 |
| SS&C Technologies Holdings, Inc. | United States | Industrials | 5.0 |
| Vontier Corp | United States | Information Technology | 4.9 |
| Bio-Techne Corporation | United States | Health Care | 4.8 |
| CoStar Group, Inc. | United States | Real Estate | 4.8 |
| Charles River Laboratories International, Inc. | United States | Health Care | 4.7 |
| Cirrus Logic, Inc. | United States | Information Technology | 4.5 |
| HealthEquity Inc | United States | Health Care | 4.3 |
| Hologic, Inc. | United States | Health Care | 4.1 |

Security level contributors and detractors

| | Security | Average Relative weight (%) | % Contribution to return |
|--------------|---------------------------|-----------------------------|--------------------------|
| Contributors | ExlService Holdings, Inc. | 4.7 | 1.2 |
| | DexCom, Inc. | 4.9 | 1.1 |
| | HealthEquity Inc | 4.3 | 1.1 |
| Detractors | Bio-Techne Corporation | 4.8 | -0.2 |
| | MAXIMUS, Inc. | 4.1 | -0.6 |
| | Cirrus Logic, Inc. | 4.4 | -0.7 |

Sector attribution relative to the benchmark

| | Sector | Average Relative weight (%) | Allocation Effect (%) | Selection Effect (%) | Total Effect (%) |
|--------------|------------------------|-----------------------------|-----------------------|----------------------|------------------|
| Contributors | Health Care | 21.3 | -1.9 | 2.6 | 0.7 |
| | Consumer Staples | -2.0 | 0.2 | 0.5 | 0.7 |
| | Materials | -5.6 | 0.7 | 0.0 | 0.7 |
| Detractors | Energy | -5.3 | -0.5 | 0.0 | -0.5 |
| | Financials | -8.0 | -0.5 | -0.6 | -1.2 |
| | Information Technology | 12.0 | 1.2 | -3.9 | -2.6 |

Commentary

US MID CAP OPPORTUNITIES

1) QFR Highlights

- For Q4 of 2024, the fund's gross return was 5.23%.
- Sector allocations are generally a residual of the security selection process. As a growth team we are typically more invested (and thus overweight) in the sectors where sustainable growth is more easily found – information technology, health care and industrials. These sectors have been long-term winners in the market. We try to diversify outside these areas by deliberately looking for companies that satisfy our criteria in other sectors.
- We focus mainly on free cash flow as a metric for company valuations. This measure has become even more important in recent years, as companies have moved increasingly to present earnings in an “adjusted” fashion, which may obscure reality.

2) Fund Performance

- For Q4 of 2024, the Fund's gross return was 5.23%, underperforming the benchmark (Russell Midcap) return of 7.15%.
- Stock selection in Health Care and an overweight allocation to Information Technology contributed to relative performance, while stock selection in Information Technology and an overweight allocation in Health Care detracted.

3) Security contributors

The top security contributors in Q4 of 2024 were ExlService Holdings, Inc., DexCom, Inc. and HealthEquity Inc.

4) Security detractors

The top security detractors in Q4 of 2024 were Cirrus Logic, Inc. and MAXIMUS, Inc.

5) Portfolio activities

A new position was opened in the Health Care sector, the fund increased positions in the Health Care and Information technology sectors while reducing positions in the Industrial sector over the last quarter.

6) Market overview

The fourth quarter in 2024 gave steady returns in the US markets with the broader market (S&P 500) returning 9.05% while the Russell Midcap Index returned 7.15%. The election results gave markets a positive stimulus based on various policy expectations, the quarter however ended on a cautious note as a result of the relatively hawkish message sent by Jerome Powell at the latest Federal Reserve meeting suggesting that further interest rate cuts are no longer guaranteed given the recent data, be it employment-related or inflation related.

7) Outlook and Positioning

We have continued to overweight Healthcare, non-cyclical Industrials, and Information Technology sectors. Sector allocations are generally a residual of the security selection process. As a growth team we are typically more invested (and thus overweight) in the sectors where sustainable growth is more easily found – information technology, health care and industrials. These sectors have been long-term winners in the market. We try to diversify outside these areas by deliberately looking for companies that satisfy our criteria in other sectors.

We do believe that many of our companies offer high value-added products and services, and this should give them reasonable pricing power. This power may serve them well if we undergo another period of inflation.

In 2022 and 2023, the drug life sciences and supply chain industry experienced a slow down in spending after the surge that it had gone through in 2020 and 2021 because of the covid-19 pandemic. This period of destocking may be close to an end entering 2025. Our holdings in this industry like Bio-Techne Corporation, Waters Corporation and Charles River Laboratories International are suppliers to the drug industry. They offer services, instruments, and consumables to the industry but are not drug companies themselves, which we usually avoid due to the binary risk of drug development.

Additionally, we recently acquired shares of Inari, a medical device company that helps patients suffering from vascular disease. This is an example of a business that we believe has differentiated intellectual property (IP).

Commentary

7) Outlook and Positioning

Elsewhere, a lot of market euphoria from Gen AI has continued from 2024 on to this year. It was interesting to see how this first caused a negative price dislocation in our holding, EXL Services, which was first perceived as a firm whose services would be replaced by AI. However, in 2024 the firm has been pivotal to AI implementation for businesses highlighted by its initiative to create enterprise-wide data and AI applications for insurance, banking, healthcare and retail.

As one can see by the recent additions to the portfolios, and the current positioning of our largest weightings, we own many businesses that could do reasonably well regardless of the economic environment. These allocations and changes have maintained a relatively low beta against our benchmark, which may prove beneficial if the global economies struggle from higher interest costs and sticky levels of inflation.

8) Stock stories

Bio-Techne Corp

- Bio-Techne is a leading supplier of high quality and innovative tools for Life Science Research, Therapeutic Manufacturing and Clinical Diagnostics.
- The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes.
- In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays.
- Bio-techne manufactures and distributes some of the world's high-quality proteins and reagents used in healthcare research and drug development. The company has expanded their portfolio in recent years to include fast growing areas like Cell & Gene Therapy, Spatial Biology, Liquid Biopsy, Molecular Diagnostics etc.

Vontier Corp

- Vontier serves the retail fueling (69% of revenue), auto repair (22%), telematics (7%), and traffic control (2%) markets.
- Next time you go to the gas station to fill up the car, the chances the fueling system and integrated POS system at the store belonging to Vontier are very high.
- A secondary business that they run is a car repair mobile service. The business is called Matco, they provide vans equipped with all the tools to repair cars on the go.
- Vontier also has a stake in EV chargers and have made acquisitions on that front.

Cirrus Logic Inc

- Cirrus Logic is a provider of analog semiconductors for audio applications and increasingly in high-performance mixed-signal applications like power management.
- Apple has long been a major customer for Cirrus, and the company is growing its content in new generations of the iPhone in areas beyond audio. As a trusted supplier, we believe Cirrus will have a chance to participate in new product categories at Apple.
- Both segments at Cirrus are targeting new avenues of growth in devices beyond the smartphone in high-end audio, fast charging and battery management and haptics. For example, Cirrus is gaining new revenues in the laptop market.

Commissions, trailing commissions, management fees, and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns as of including changes in share value and reinvestment of all distributions and does not take into account sales, redemption, distribution, or optional charges or income taxes payable by any security holder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. Index performance does not include the impact of fees, commissions, and expenses that would be payable by investors in the investment products that seek to track an index.

This document may contain forward-looking information which reflect our or third party current expectations or forecasts of future events. Forward-looking information is inherently subject to, among other things, risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed herein. These risks, uncertainties and assumptions include, without limitation, general economic, political and market factors, interest and foreign exchange rates, the volatility of equity and capital markets, business competition, technological change, changes in government regulations, changes in tax laws, unexpected judicial or regulatory proceedings and catastrophic events. Please consider these and other factors carefully and not place undue reliance on forward-looking information. The forward-looking information contained herein is current only as of . There should be no expectation that such information will in all circumstances be updated, supplemented or revised whether as a result of new information, changing circumstances, future events or otherwise.

The content of this commentary (including facts, views, opinions, recommendations, descriptions of or references to, products or securities) is not to be used or construed as investment advice, as an offer to sell or the solicitation of an offer to buy, or an endorsement, recommendation or sponsorship of any entity or security cited. Although we endeavour to ensure its accuracy and completeness, we assume no responsibility for any reliance upon it.

Standard deviation provides a measure of the variability of returns that have occurred relative to the average return. The higher the standard deviation, the greater is the range of returns that has been experienced. Standard deviation is commonly used as a measure of risk.

Percentile rankings are from Morningstar Research Inc., an independent research firm, based on the category and reflect the performance of the for the 3-month, 1-, 3-, 5- and 10-year periods as of . The percentile rankings compare how a fund has performed relative to other funds in a particular category and are subject to change monthly. The number of category funds for for each period are as follows: one year - 0 ; three years - 0 ; five years - 0 ; ten years - 0.

© Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Morningstar data is shown as of the most recent reporting period by each fund family. Allocations may not equal 100% and will vary overtime. Assets contained within "Other" category are not classified by Morningstar. All information presented in this tool is for informational purposes only and is not intended to be investment advice. The information is not meant to be an offer to sell or a recommendation to buy any investment product. Unless otherwise noted, performance is shown before sales charge. For more fund information, click the POS Documents link.

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

This material is for informational and educational purposes only. It is not a recommendation of any specific investment product, strategy, or decision, and is not intended to suggest taking or refraining from any course of action. It is not intended to address the needs, circumstances, and objectives of any specific investor. Mackenzie Investments, which earns fees when clients select its products and services, is not offering impartial advice in a fiduciary capacity in providing this sales and marketing material. This information is not meant as tax or legal advice. Investors should consult a professional advisor before making investment and financial decisions and for more information on tax rules and other laws, which are complex and subject to change.

© Mackenzie Investments. All rights reserved.